Dublin, Dec. 21, 2016 -- Research and Markets has announced the addition of the "Glaucoma Drugs Price Analysis and Strategies - 2016" report to their offering.
Glaucoma Drugs Price Analysis and Strategies 2016, provides drug pricing data and benchmarks in the global Glaucoma market.
The research answers the following questions:
- What are the key drugs marketed for Glaucoma and their clinical attributes? How are they positioned in the Global Glaucoma market?
- What are the unit prices and annual treatment cost for Glaucoma therapies in different countries? What are the drug pricing trends and how are they expected to change in the future? How are the drug pricing and reimbursement landscape different by countries?
- What are the unmet needs in the global Glaucoma drugs market? What would be the ideal pricing strategy for a new pipeline therapy for Glaucoma?
Research Scope:
- Treatment Options - Identify key drugs marketed and prescribed for Glaucoma including trade name, molecule name, and company
- Drugs Attributes - Find out the safety, efficacy, and risk benefit for key drugs marketed for Glaucoma
- Market Positioning - Identify how drugs are clinically and commercially positioned in the global Glaucoma market
- Glaucoma Drugs Price Analysis - Find out the annual therapy cost and unit price for key drugs marketed
- Find out how the price advanced from 2012 and forecast to 2021
- Pricing & Reimbursement Landscape - Find out the pricing and reimbursement landscape
- Glaucoma New Drug Pricing - Identify the effective pricing strategy for a new drug launch
Key Topics Covered:
1. Treatment Options
2. Drugs Clinical Attributes
3. Drugs Market Positioning
4. Drugs Price Analysis
5. Drugs Price Benchmarks
6. Drug Pricing & Reimbursement Landscape
7. Drugs Price Forecast
8. Market Unmet Needs
9. New Drug Pricing
For more information about this report visit http://www.researchandmarkets.com/research/kj6p6h/glaucoma_drugs
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Optical


Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Bank of America's $72.5M Epstein Settlement: What You Need to Know
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 



